Rachel McMinn insider trades

Open-market stock purchases and sales by Rachel McMinn, Chief Executive Officer at Neurogene Inc, from SEC Form 4 filings since Apr 30, 2014.

Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +19%.

Recent trades

DateStockTradeValue
Sep 22, 2026NGNE Neurogene IncBought (not open market)—
Mar 26, 2026NGNE Neurogene IncSold$74K
Feb 20, 2026NGNE Neurogene IncBought (not open market)—
Feb 20, 2026NGNE Neurogene IncBought (not open market)—

Companies traded

  • NGNE Neurogene Inc: 1 buy, 1 sale, last Sep 22, 2026
  • ICPT Intercept Pharmaceuticals Inc: 16 sales, last Oct 2, 2017

Get free alerts when Rachel McMinn files a new trade →